Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 11 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has received final approval from the USFDA for Jaythari (Deflazacort) Tablets in various strengths. Deflazacort is a corticosteroid used to treat Duchenne muscular dystrophy in patients aged five and older. The tablets will be manufactured at the Doppel Farmaceutici S.r.l. facility in Italy.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 11, 2025, titled "Zydus receives final approval from USFDA for Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases